Related Experiment Video
Updated: Aug 5, 2026

03:42
A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
An NRIP1-Centric Monocyte Immunogenetic Bridge Between Heart Failure and Ischemic Stroke
Hongyao Chen1, Yao Xiao1, Xiaoyan Yang1
1School of Informatics, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic of China.
Journal of Inflammation Research
|August 3, 2026
Summary
Heart failure and ischemic stroke share an immune bridge, with NRIP1-expressing monocytes playing a key role. Tretinoin, a small molecule, shows potential for treating this comorbidity by targeting NRIP1.
Area of Science:
- Immunology
- Cardiology
- Neurology
Background:
- Heart failure (HF) and ischemic stroke (IS) frequently co-occur, exacerbating each other.
- Circulating immune cells are implicated as a potential inflammatory bridge between these conditions.
- Key immune mediators and therapeutic targets remain largely undefined.
Purpose of the Study:
- To identify the specific immune cell lineage linking HF and IS.
- To pinpoint candidate genes and druggable targets involved in HF-IS comorbidity.
- To explore potential therapeutic interventions.
Main Methods:
- Bidirectional Mendelian randomization (MR) using genome-wide association study data.
- Single-cell transcriptomic analysis of HF and IS mouse models.
- Integration of genetic data, spatial transcriptomics, and in vitro validation.
- In silico drug prediction and molecular dynamics simulations.
Main Results:
- MR confirmed a bidirectional causal link between HF and IS.
- Expansion of inflammatory Ly6C+ monocytes was observed in both HF and IS models.
- NRIP1 was identified as a key gene, with its expression in monocytes mediating the HF-IS link.
- Retinoic acid-related small molecules, including tretinoin, showed potential for NRIP1-targeted therapy.
Conclusions:
- An NRIP1-centered monocyte network acts as a potential immune bridge in HF-IS comorbidity.
- Tretinoin represents a promising therapeutic entry point for NRIP1-targeted intervention.
- This study elucidates a novel mechanism and therapeutic strategy for co-occurring HF and IS.